"rationale","name","id","uuid:ID","description","label","instanceType"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","StudyDesign_1","d4dc04c5-8902-4ef5-bf77-0e02a82a2ce7","The main design for the study","","StudyDesign"
